Arno Therapeutics Engages The Ruth Group for Investor Relations and Public Relations Counsel
March 19 2013 - 8:30AM
Arno Therapeutics, Inc. (OTCBB:ARNI), a clinical stage
biopharmaceutical company focused on the development of oncology
therapeutics, today announced that the company has engaged The Ruth
Group as its public relations and investor relations agency of
record.
By retaining The Ruth Group, Arno strengthens its communications
efforts in advance of significant upcoming milestones. Those
milestones include the Company's data presentation at the AACR
Annual Meeting 2013 in April and the initiation of Phase 1 clinical
studies in onapristone, an oral anti-progestin cancer therapy,
anticipated in the second half of 2013.
Glenn Mattes, President and CEO of Arno, stated, "The Ruth
Group's expertise, established relationships, and strategic counsel
in investor relations, and their deep rooted experience in media
relations, will help Arno gain visibility with multiple audiences.
We are confident that their professionals will assist us in
communicating both the progress we are making, as well as the
fundamental value of our therapeutic candidates, to both the life
sciences investment community and the larger biopharmaceutical
industry. We look forward to leveraging The Ruth Group's expertise
as we continue to make progress on developing and advancing our
unique product candidates."
The Ruth Group (www.theruthgroup.com) will assist Arno by
increasing awareness of the Company's corporate focus and growth
strategy across the investment community. The Ruth Group will also
focus on highlighting the Company's corporate profile among
healthcare and biotech industry leaders.
About Arno Therapeutics
Arno Therapeutics is a clinical stage biopharmaceutical company
developing innovative products for the treatment of cancer. Arno
has exclusive worldwide rights to develop and market three
innovative anti-cancer product candidates. These compounds
are in clinical or preclinical development as potential best- or
first-in-class products to treat hematologic malignancies and solid
tumors. For more information about the company, please
visit www.arnothera.com.
About The Ruth Group
The Ruth Group is an investor relations and public relations
firm solely focused on life sciences. The firm's professionals
offer clients in-depth strategic counsel, and unmatched expertise
and knowledge. The Ruth Group's immersion in its clients'
challenges and opportunities allows for a unique ability to craft
clear communications to meet clients' corporate objectives, and its
boutique structure translates to flexibility, creative thinking,
and rapid responsiveness. Located in the heart of New York
City, and led by founder and CEO Carol Ruth, The Ruth Group shares
the fierce passion, energy, innovation, and determination of its
clients.
Forward-Looking Statements: This press
release contains forward-looking statements that involve
substantial risks and uncertainties. These statements are often,
but not always, made through the use of words or phrases such as
"anticipates," "expects," "plans," "believes," "intends," and
similar words or phrases. These forward-looking statements include,
without limitation, statements regarding the timing, progress and
anticipated results of the clinical development of onapristone, and
Arno's strategy, future operations, outlook, milestones, future
financial position, future financial results, plans and objectives.
We may not actually achieve these plans, intentions or expectations
and Arno cautions investors not to place undue reliance on our
forward-looking statements. Actual results or events could differ
materially from the plans, intentions and expectations disclosed in
the forward-looking statements we make. Various important factors
could cause actual results or events to differ materially from the
forward-looking statements that we make. Such factors include,
among others, risks that the results of clinical trials will not
support our claims or beliefs concerning the effectiveness of
onapristone or any of our other product candidates, our ability to
finance the development of our product candidates, regulatory
risks, and our reliance on third party researchers and other
collaborators. Additional risks are described in the company's
Annual Report on Form 10-K for the year ended December 31,
2011 and Quarterly Report on Form 10-Q for the quarter
ended September 30, 2012. Arno is providing this information
as of the date of this press release and does not undertake any
obligation to update any forward-looking statements as a result of
new information, future events or otherwise.
CONTACT: The Ruth Group
Stephanie Carrington (investors)
scarrington@theruthgroup.com
(646) 536-7017
Caitlin Cox (media)
ccox@theruthgroup.com
(646) 536-7033
Arno Therapeutics
Glenn Mattes
gm@arnothera.com
862-703-7176
Arno Therapeutics (CE) (USOTC:ARNI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Arno Therapeutics (CE) (USOTC:ARNI)
Historical Stock Chart
From Jul 2023 to Jul 2024